
Lamson D. Nguyen
Examiner (ID: 17152, Phone: (571)272-2259 , Office: P/2853 )
| Most Active Art Unit | 2861 |
| Art Unit(s) | 2861, 2853 |
| Total Applications | 2316 |
| Issued Applications | 2225 |
| Pending Applications | 18 |
| Abandoned Applications | 89 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18178550
[patent_doc_number] => 20230039279
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => INFLAMMATION-RESPONSIVE ANTI-INFLAMMATORY HYDROGELS
[patent_app_type] => utility
[patent_app_number] => 17/782908
[patent_app_country] => US
[patent_app_date] => 2020-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15873
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17782908
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/782908 | INFLAMMATION-RESPONSIVE ANTI-INFLAMMATORY HYDROGELS | Dec 6, 2020 | Pending |
Array
(
[id] => 18148188
[patent_doc_number] => 20230022045
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-26
[patent_title] => COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 17/782147
[patent_app_country] => US
[patent_app_date] => 2020-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13546
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17782147
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/782147 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | Dec 2, 2020 | Pending |
Array
(
[id] => 18545285
[patent_doc_number] => 11718625
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-08
[patent_title] => Near-infrared fluorescent molecule active targeting folate receptor and preparation method thereof
[patent_app_type] => utility
[patent_app_number] => 17/596423
[patent_app_country] => US
[patent_app_date] => 2020-11-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 2570
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17596423
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/596423 | Near-infrared fluorescent molecule active targeting folate receptor and preparation method thereof | Nov 26, 2020 | Issued |
Array
(
[id] => 18159324
[patent_doc_number] => 20230025916
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-26
[patent_title] => BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/779226
[patent_app_country] => US
[patent_app_date] => 2020-11-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20072
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17779226
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/779226 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 AND USES THEREOF | Nov 26, 2020 | Abandoned |
Array
(
[id] => 18241912
[patent_doc_number] => 20230074223
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-09
[patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF MASTITIS
[patent_app_type] => utility
[patent_app_number] => 17/756428
[patent_app_country] => US
[patent_app_date] => 2020-11-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20915
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17756428
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/756428 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MASTITIS | Nov 26, 2020 | Abandoned |
Array
(
[id] => 18142343
[patent_doc_number] => 20230016187
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-19
[patent_title] => TREM-1 INHIBITORS FOR THE TREATMENT OF VASO-OCCLUSIONS AND TISSUE INJURIES IN PATIENTS SUFFERING FROM SICKLE CELL DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/778571
[patent_app_country] => US
[patent_app_date] => 2020-11-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7707
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17778571
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/778571 | TREM-1 INHIBITORS FOR THE TREATMENT OF VASO-OCCLUSIONS AND TISSUE INJURIES IN PATIENTS SUFFERING FROM SICKLE CELL DISEASE | Nov 23, 2020 | Pending |
Array
(
[id] => 18108066
[patent_doc_number] => 20230000946
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => UK 114 SALMON PROTEINS FOR USE IN THE TREATMENT, DIAGNOSIS AND PREVENTION OF MALIGNANT TUMOURS
[patent_app_type] => utility
[patent_app_number] => 17/756262
[patent_app_country] => US
[patent_app_date] => 2020-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2338
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17756262
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/756262 | UK 114 SALMON PROTEINS FOR USE IN THE TREATMENT, DIAGNOSIS AND PREVENTION OF MALIGNANT TUMOURS | Nov 22, 2020 | Pending |
Array
(
[id] => 19081863
[patent_doc_number] => 20240108664
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-04
[patent_title] => TUMOR-TARGETING SALMONELLA GALLINARUM STRAIN AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/768567
[patent_app_country] => US
[patent_app_date] => 2020-10-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6228
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17768567
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/768567 | TUMOR-TARGETING SALMONELLA GALLINARUM STRAIN AND USE THEREOF | Oct 28, 2020 | Pending |
Array
(
[id] => 20577340
[patent_doc_number] => 12569577
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-03-10
[patent_title] => PSMA-targeting imaging agents
[patent_app_type] => utility
[patent_app_number] => 17/770382
[patent_app_country] => US
[patent_app_date] => 2020-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 6572
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 104
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17770382
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/770382 | PSMA-targeting imaging agents | Oct 27, 2020 | Issued |
Array
(
[id] => 16853589
[patent_doc_number] => 20210154334
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-27
[patent_title] => DUAL-TARGETED CARBONIC ANHYDRASE IX COMPLEX AND CONTRAST AGENT THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/079691
[patent_app_country] => US
[patent_app_date] => 2020-10-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2919
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17079691
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/079691 | Dual-targeted carbonic anhydrase ix complex and contrast agent thereof | Oct 25, 2020 | Issued |
Array
(
[id] => 16657286
[patent_doc_number] => 20210053922
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-25
[patent_title] => 18F - TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND THEIR USE AS IMAGING AGENTS FOR PROSTATE CANCER
[patent_app_type] => utility
[patent_app_number] => 17/079013
[patent_app_country] => US
[patent_app_date] => 2020-10-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9340
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 153
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17079013
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/079013 | 18F - TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND THEIR USE AS IMAGING AGENTS FOR PROSTATE CANCER | Oct 22, 2020 | Abandoned |
Array
(
[id] => 19096517
[patent_doc_number] => 20240115744
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-11
[patent_title] => FIBRIN-BINDING COMPOUNDS FOR IMAGING AND TREATMENT
[patent_app_type] => utility
[patent_app_number] => 17/767956
[patent_app_country] => US
[patent_app_date] => 2020-10-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22906
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -71
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17767956
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/767956 | FIBRIN-BINDING COMPOUNDS FOR IMAGING AND TREATMENT | Oct 22, 2020 | Pending |
Array
(
[id] => 18077339
[patent_doc_number] => 20220402951
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => RADIOISOTOPE LABELED COMPOUND FOR IMAGING OR TREATMENT OF PROSTATE CANCER
[patent_app_type] => utility
[patent_app_number] => 17/770315
[patent_app_country] => US
[patent_app_date] => 2020-10-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9806
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17770315
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/770315 | Radioisotope labeled compound for imaging or treatment of prostate cancer | Oct 21, 2020 | Issued |
Array
(
[id] => 18065517
[patent_doc_number] => 20220396604
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-15
[patent_title] => COMPOSITIONS COMPRISING MODIFIED SMARCB1 AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/770464
[patent_app_country] => US
[patent_app_date] => 2020-10-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 67392
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -39
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17770464
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/770464 | COMPOSITIONS COMPRISING MODIFIED SMARCB1 AND USES THEREOF | Oct 20, 2020 | Pending |
Array
(
[id] => 18019147
[patent_doc_number] => 20220370646
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => PHARMACEUTICAL COMPOSITIONS OF GD-BASED CONTRAST AGENTS
[patent_app_type] => utility
[patent_app_number] => 17/771168
[patent_app_country] => US
[patent_app_date] => 2020-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3991
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17771168
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/771168 | PHARMACEUTICAL COMPOSITIONS OF GD-BASED CONTRAST AGENTS | Oct 19, 2020 | Pending |
Array
(
[id] => 18550854
[patent_doc_number] => 20230248854
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => METHOD FOR PRODUCING RADIOACTIVE METAL-LABELED ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 17/769657
[patent_app_country] => US
[patent_app_date] => 2020-10-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13471
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17769657
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/769657 | METHOD FOR PRODUCING RADIOACTIVE METAL-LABELED ANTIBODY | Oct 15, 2020 | Pending |
Array
(
[id] => 17944437
[patent_doc_number] => 20220331454
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-20
[patent_title] => IRON(III) COMPLEXES HAVING NEW CONTRAST AGENT PROPERTIES, FOR MAGNETIC RESONANCE IMAGING
[patent_app_type] => utility
[patent_app_number] => 17/642668
[patent_app_country] => US
[patent_app_date] => 2020-10-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5179
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 159
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17642668
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/642668 | Iron(III) complexes having new contrast agent properties, for magnetic resonance imaging | Oct 15, 2020 | Issued |
Array
(
[id] => 19020492
[patent_doc_number] => 20240076663
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-07
[patent_title] => PEPTIDE-NUCLEIC ACID COMPLEX HAVING BLOOD-BRAIN BARRIER PENETRATION ABILITY AND COMPOSITION COMPRISING SAME
[patent_app_type] => utility
[patent_app_number] => 17/766708
[patent_app_country] => US
[patent_app_date] => 2020-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9809
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17766708
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/766708 | PEPTIDE-NUCLEIC ACID COMPLEX HAVING BLOOD-BRAIN BARRIER PENETRATION ABILITY AND COMPOSITION COMPRISING SAME | Oct 14, 2020 | Abandoned |
Array
(
[id] => 20401295
[patent_doc_number] => 12491255
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-09
[patent_title] => EPCAM binding fibronectin type III domains
[patent_app_type] => utility
[patent_app_number] => 17/768711
[patent_app_country] => US
[patent_app_date] => 2020-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11345
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17768711
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/768711 | EPCAM binding fibronectin type III domains | Oct 13, 2020 | Issued |
Array
(
[id] => 19049418
[patent_doc_number] => 20240091387
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-21
[patent_title] => METHODS AND SYSTEMS USING PEPTIDES FOR TARGETING AND MAPPING HUMAN NERVES IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY
[patent_app_type] => utility
[patent_app_number] => 17/767847
[patent_app_country] => US
[patent_app_date] => 2020-10-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48165
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 304
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17767847
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/767847 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | Oct 8, 2020 | Issued |